Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spectris Q1 sales slip, continues to expect 'strong progress' in FY25

(Sharecast News) - Precision instrumentation supplier Spectris said on Wednesday that it continues to expect "strong progress" in 2025 despite the "uncertain macroeconomic environment" created by Donald Trump's "reciprocal" tariffs. Spectris said recent softness had continued into Q1, with uncertainty impacting certain end markets, delaying deliveries and order intake.

On a constant currency basis, Q1 sales were 2% lower year-on-year at £299.0m, while Spectris' order book was up 4% at £529.0m, with a book-to-bill ratio of 1.07x.

However, the FTSE 100-listed group highlighted that it continues to expect to deliver "strong growth" in adjusted operating profits in 2025, in line with market expectations, whilst still being mindful of the uncertain macroeconomic environment, noting that its "strong market positions", as well as its ability to apply surcharges, should help it to offset the direct impact of tariffs.

Chief executive Andrew Heath said: "We continue to make strong progress in executing our strategy, while also retaining a tight control on costs and working closely with our customers as they navigate current market dynamics. Customers' need for the highest quality products will continue to drive demand.

"While the indirect tariff impact on end market demand is unclear at this early stage, we expect to be able to mitigate the direct impact of tariffs, supported by our strong, differentiated market positions, the importance of Spectris' products to our customers, and the Group's global operational footprint."

As of 0830 BST, Spectris shares were down 0.40% at 1,994.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.